Results from a phase II study indicate that the PD-L1 inhibitor atezolizumab, recently approved for advanced bladder cancer that's refractory to standard platinum chemotherapy, is effective as first-line therapy for this disease. Durable responses to atezolizumab were seen in nearly a quarter of the study patients, who were all ineligible to receive cisplatin.
from Cancer via ola Kala on Inoreader http://ift.tt/2arSTwJ
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου